HYDROCORTISONE, PREDNISOLONE ACETATE PH. EUR., ASCIMINIB HYDROCHLORIDE, CYTARABINE, DEXAMETHASONE, BLINATUMOMAB, Asciminib, METHOTREXATE, DBL methotrexate injection, VINCRISTINE SULFATE, DEXAMETHASONE SODIUM PHOSPHATE
CABL001L12101
Phase 2 small_molecule active
Quick answer
HYDROCORTISONE, PREDNISOLONE ACETATE PH. EUR., ASCIMINIB HYDROCHLORIDE, CYTARABINE, DEXAMETHASONE, BLINATUMOMAB, Asciminib, METHOTREXATE, DBL methotrexate injection, VINCRISTINE SULFATE, DEXAMETHASONE SODIUM PHOSPHATE for relapsed or refractory BCR::ABL1-positive (Philadelphia positive, Ph+) or BCR::ABL1-like (Ph-like) acute lymphoblastic leukemia (ALL) is a Phase 2 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- relapsed or refractory BCR::ABL1-positive (Philadelphia positive, Ph+) or BCR::ABL1-like (Ph-like) acute lymphoblastic leukemia (ALL)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active